Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A single cell RNA-seq analysis
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217809 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Ganji Purnachandra Nagaraju und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Carcinoma, Pancreatic Ductal, Deoxycytidine, Pancreatic Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 104 Literaturangaben.
Abstract (Originalsprache)
Epithelial-mesenchymal transition (EMT) describes a process by which epithelial cells acquire mesenchymal properties associated with increased migration, invasion, and resistance to therapy. In pancreatic ductal adenocarcinoma (PDAC), targeting the molecular and intercellular communication pathways that drive EMT represents a promising therapeutic strategy. Here, we investigate the effects of combined treatment with gemcitabine (G), paricalcitol (P), and hydroxychloroquine (GPH) in KPC-Luc orthotopic mouse models of PDAC, using single-cell RNA sequencing (scRNA-seq), high-dimensional weighted gene co-expression network analysis (hdWGCNA), and cell-cell communication analysis. GPH treatment reduces EMT, which is associated with the downregulation of the essential gene fibronectin (Fn1). Collagen and Fn1 pathways co-expression decreases in GPH-treated KPC-Luc tumors. Cancer-associated fibroblasts (CAFs) appear dominant in collagen signaling, whereas macrophages mediate Fn1 signaling. GPH treatment reduces the expression interaction strength between ligands and receptors (collagen-integrin and Fn1-Cd44 or Fn1-Sdc4) compared to sham, PH, and G. Altogether, this study presents a comprehensive single-cell resolution map of the molecular and cellular mechanisms by which GPH treatment impairs EMT in PDAC, identifying potential therapeutic targets within the fibronectin and collagen signaling axes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
- Functional Genomics Core, University of California, Irvine, CA, 92697, USA.
- Indiana University School of Medicine, Indianapolis, IN-46202, USA.
- Department of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA. Electronic address: belrayes@uabmc.edu.
Zitieren
APA
Nagaraju, G. P., Saddala, M. S., Sarvesh, S., Bandi, D. S. R., Khaliq, A. M., Masood, A., Akce, M., & El-Rayes, B. F. (2025). Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A single cell RNA-seq analysis. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217809
Vancouver
Nagaraju GP, Saddala MS, Sarvesh S, Bandi DSR, Khaliq AM, Masood A, et al. Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A single cell RNA-seq analysis. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217809
BibTeX
@article{Nagaraju2025,
author = {Nagaraju, Ganji Purnachandra and Saddala, Madhu Sudhana and Sarvesh, Sujith and Bandi, Dhana Sekhar Reddy and Khaliq, Ateeq M and Masood, Ashiq and Akce, Mehmet and El-Rayes, Bassel F},
title = {Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A single cell RNA-seq analysis},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217809}
}
EUVIMED